TRTL-913

How it works

A drug that boosts signalling through GABA-A receptors, the brain's main inhibitory system, to counter the loss of central inhibition repeatedly implicated in tinnitus, reduced GABAergic inhibition is one documented driver of dorsal-cochlear-nucleus hyperactivity. It targets that broad excitation, inhibition imbalance rather than a single circuit catalogued here, so no specific hypothesis is asserted. Backed by Tortugas Neuroscience and described as Phase 2-ready.

This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.